Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $18.40 in the prior trading day, Pacira BioSciences Inc (NASDAQ: PCRX) closed at $18.63, up 1.25%. In other words, the price has increased by $1.25 from its previous closing price. On the day, 0.58 million shares were traded. PCRX stock price reached its highest trading level at $19.16 during the session, while it also had its lowest trading level at $18.17.
Ratios:
Our goal is to gain a better understanding of PCRX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.90 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.46. For the most recent quarter (mrq), Quick Ratio is recorded 1.89 and its Current Ratio is at 2.25. In the meantime, Its Debt-to-Equity ratio is 0.86 whereas as Long-Term Debt/Eq ratio is at 0.58.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Truist on August 13, 2024, Downgraded its rating to Sell and sets its target price to $8 from $30 previously.
On August 12, 2024, RBC Capital Mkts Downgraded its rating to Sector Perform which previously was Outperform and also lowered its target price recommendation from $37 to $14.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 06 ’25 when SLONIN JONATHAN sold 879 shares for $18.40 per share. The transaction valued at 16,174 led to the insider holds 93,444 shares of the business.
SLONIN JONATHAN bought 879 shares of PCRX for $16,174 on Jan 06 ’25. On Dec 13 ’24, another insider, GAUGLER DARYL, who serves as the Chief Operating Officer of the company, sold 500 shares for $19.76 each. As a result, the insider received 9,880 and left with 115,200 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCRX now has a Market Capitalization of 860206656 and an Enterprise Value of 1050820480. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.24 while its Price-to-Book (P/B) ratio in mrq is 1.15. Its current Enterprise Value per Revenue stands at 1.512 whereas that against EBITDA is 5.902.
Stock Price History:
The Beta on a monthly basis for PCRX is 0.76, which has changed by -0.4701987 over the last 52 weeks, in comparison to a change of 0.24933672 over the same period for the S&P500. Over the past 52 weeks, PCRX has reached a high of $35.95, while it has fallen to a 52-week low of $11.16. The 50-Day Moving Average of the stock is 3.45%, while the 200-Day Moving Average is calculated to be -12.13%.
Shares Statistics:
The stock has traded on average 676.99K shares per day over the past 3-months and 797310 shares per day over the last 10 days, according to various share statistics. A total of 46.15M shares are outstanding, with a floating share count of 44.69M. Insiders hold about 3.45% of the company’s shares, while institutions hold 112.56% stake in the company. Shares short for PCRX as of 1734048000 were 4750188 with a Short Ratio of 7.02, compared to 1731628800 on 4822169. Therefore, it implies a Short% of Shares Outstanding of 4750188 and a Short% of Float of 14.979999999999999.
